Skip to main content

United States News All stories

Every story in this section, newest first — page 141 of 373.

Grafa
Insights

WiseTech shares plunge amid federal fraud investigation

  • Federal authorities are investigating WiseTech Global (ASX:WTC) executive chairman Richard White over visa fraud and human trafficking allegations.
  • The ongoing controversy triggered a sharp market sell-off, pulling the WiseTech share price down to $36.88.
  • Institutional investors are reassessing sector governance and operational risk amid wider software industry headwinds.
Read more: WiseTech shares plunge amid federal fraud investigation
Grafa

Replimune receives FDA acceptance of resubmitted BLA for RP1 in advanced melanoma

Replimune (NASDAQ:REPL) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.

Read more: Replimune receives FDA acceptance of resubmitted BLA for RP1 in advanced melanoma
Grafa
Energy

PowerBank wins US federal contract for solar and EV charging project

PowerBank (NASDAQ:PBK) announced that its US subsidiary, Abundant Solar Power, has been awarded a contract by the United States Department of Defense and the Department of the Army to construct a photovoltaic array, electric vehicle chargers, and associated infrastructure at the Armed Forces Reserve Center in Farmingdale, New York.

Read more: PowerBank wins US federal contract for solar and EV charging project
Grafa

Incyte receives positive CHMP opinion for Opzelura in moderate atopic dermatitis

Incyte (NASDAQ:INCY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate.

Read more: Incyte receives positive CHMP opinion for Opzelura in moderate atopic dermatitis
Grafa

Datroway receives positive CHMP opinion for first-line TNBC in EU

Daiichi Sankyo and AstraZeneca (NYSE:AZN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Datroway (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

Read more: Datroway receives positive CHMP opinion for first-line TNBC in EU
Grafa

Acadia Pharmaceuticals receives positive CHMP opinion for DAYBU

Acadia Pharmaceuticals (NASDAQ:ACAD) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.

Read more: Acadia Pharmaceuticals receives positive CHMP opinion for DAYBU